Concord Biotech Limited
CONCORDBIO · General/Diversified · NSE
₹1,048
Current Market Price
Fair Value (DCF)
₹648
Margin of Safety
-38.2%
Updated just now
YieldIQ Score
43/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
53%
ROE
20.5%
Debt/Equity
0.00
WACC
10.3%
Market Cap
₹0.11 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
26.8%
Return on capital employed
EV / EBITDA
23.1×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
934.1×
EBIT covers interest
Current Ratio
6.17×
Short-term liquidity
Asset Turnover
0.56×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,047.5
Bear case
₹385.25
MoS -171.9%
Base case
₹647.85
MoS -61.7%
Bull case
₹844.22
MoS -24.1%
Ratio Trends
CONCORDBIO · last 4 annual periods
ROE
20.5%
ROCE
30.3%
Operating Margin
—
Debt / Equity
0.00×
PE
—
EV / EBITDA
—
Historical Financials
CONCORDBIO · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹708 Cr | ₹831 Cr | ₹319 Cr | ₹1180 Cr | +18.5% |
| EBITDA | ₹293 Cr | ₹381 Cr | ₹469 Cr | ₹549 Cr | +23.3% |
| EBIT | — | — | ₹131 Cr | — | +0.0% |
| PAT | ₹175 Cr | ₹240 Cr | ₹95.0 Cr | ₹372 Cr | +28.6% |
| EPS (diluted) | — | — | ₹9.08 | — | +0.0% |
| CFO | ₹207 Cr | ₹246 Cr | ₹265 Cr | ₹245 Cr | +5.6% |
| CapEx | ₹-156 Cr | ₹-145 Cr | — | ₹-111 Cr | — |
| FCF | ₹52.0 Cr | ₹101 Cr | — | ₹133 Cr | +36.9% |
| Total Assets | ₹1313 Cr | ₹1514 Cr | ₹1701 Cr | ₹2034 Cr | +15.7% |
| Total Debt | ₹62.5 Cr | ₹31.5 Cr | ₹6.2 Cr | ₹3.0 Cr | -63.8% |
| Shareholders' Equity | ₹1103 Cr | ₹1290 Cr | ₹1527 Cr | ₹1813 Cr | +18.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CONCORDBIO vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| BLUEJET BLUEJET | — | — | Pending | 26.9% | — |
| ONESOURCE ONESOURCE | — | — | Pending | -0.3% | — |
| SUPRIYA SUPRIYA | — | — | Pending | 18.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for CONCORDBIO in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Concord Biotech Limited has a current price of 1047.50 and a fair value of 647.85, with an ROCE of 26.8% and ROE of 20.5%, and a debt-to-...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CONCORDBIO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CONCORDBIO →
Compare
Head-to-head with peers
Compare CONCORDBIO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CONCORDBIONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.